Extended-dose Chloroquine (ECQ) for Resistant Falciparum Malaria Among Afghan Refugees in Pakistan

Clinical Trial of Extended-dose Chloroquine Versus Standard Chloroquine Treatment for Resistant Falciparum Malaria Among Afghan Refugees in NWFP Pakistan

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01019408

Acronym

ECQNWFP

Enrollment

163

Registered

2009-11-25

Start date

1993-11-30

Completion date

1995-01-31

Last updated

2009-11-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malaria, Falciparum

Keywords

Clinical Trial, Chloroquine, Refugees, Afghanistan, Pakistan

Brief summary

The purpose of this study was to provide stronger evidence for extended-dose chloroquine treatment of falciparum-positive Afghan refugees in Northwest Frontier Province (NWFP), Pakistan or justification for discontinuation of the policy.

Detailed description

To determine whether extended-dose chloroquine provided better cure rates and fewer recrudescences than standard chloroquine treatment among Afghan refugees, 163 falciparum patients from three Afghan refugee camps were recruited into 3-day (CQ 25mg/kg) or 5-day (CQ 40mg/kg) treatment arms and followed for up to 60 days.

Interventions

DRUGChloroquine

Comparison of two different dosages of chloroquine for treatment of falciparum malaria in Afghan refugee camps in Northwest Frontier Province, Pakistan

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

6 Months to 60 Years

Healthy volunteers

Inclusion criteria

* slide-confirmed infection with P. falciparum only * initial parasite density of 1000-100,000 asexual parasites/μl * absence of severe malnutrition * ability to attend stipulated follow-up visits and easy access to facility * informed consent provided by patient or parent/guardian * absence of history of hypersensitivity reactions to CQ

Exclusion criteria

* infants under six months old * pregnancy or lactation * underlying chronic severe illness * patients with other febrile illnesses * parasitaemia outside the range of 1000-100,000 asexual parasites/µl * severe malaria

Design outcomes

Primary

Measure	Time frame
therapeutic and parasitological cure with no recrudescence	60 days

Secondary

Measure	Time frame
parasite clearance time	28 days
fever clearance time	28 days
gametocytaemia	28 days

Countries

Pakistan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026